Description

CJC-1295 (no DAC), Ipamorelin 10mg (Blend) is a high-purity, research-grade peptide blend supplied as a lyophilized (freeze-dried) powder in a single sterile vial. This 10mg vial typically contains 5mg CJC-1295 (no DAC) (also known as Mod GRF 1-29) and 5mg Ipamorelin, formulated for synergistic investigation of the growth hormone (GH) axis. The product is intended exclusively for laboratory and scientific research purposes, such as in vitro studies, cell culture, animal models, or biochemical assays. It is not approved for human consumption, therapeutic use, medical treatment, or veterinary applications by any regulatory agency (e.g., FDA, EMA). All handling must be performed by qualified professionals following strict research protocols.

Key Specifications

Blend Composition: CJC-1295 (no DAC) 5mg + Ipamorelin 5mg (total 10mg per vial)
Form: White to off-white lyophilized powder
Purity: ≥98–99% (verified by HPLC; third-party Certificate of Analysis recommended)
Appearance: Lyophilized solid in sterile vial
Reconstitution: Requires bacteriostatic water, sterile water, or appropriate buffer (gentle swirling recommended; avoid vigorous agitation to prevent degradation)
Storage: Lyophilized — store at -20°C or colder, protected from light and moisture. After reconstitution — refrigerate at 2–8°C and use promptly (stability varies by conditions; typically days to weeks)

Individual Peptide Details

CJC-1295 (no DAC) / Mod GRF 1-29

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: ~3367.9 g/mol
Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
CAS Number: 863288-34-0 (related)
Mechanism: Synthetic analog of growth hormone-releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotrophs, stimulating cAMP/PKA pathways to promote pulsatile GH synthesis and release. Without the Drug Affinity Complex (DAC), it has a shorter half-life (~30 minutes), mimicking natural physiological GH pulses more closely than DAC versions.

Ipamorelin

Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: 711.85 g/mol
Amino Acid Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
CAS Number: 170851-70-4
Mechanism: Selective ghrelin mimetic and growth hormone secretagogue receptor (GHS-R1a) agonist. It triggers Gq/11-coupled calcium signaling, leading to GH release with high specificity—minimal impact on prolactin, cortisol, ACTH, or other pituitary hormones.

Research Background and Synergistic Effects

The CJC-1295 (no DAC) + Ipamorelin blend combines two complementary GH secretagogues acting via distinct pathways: GHRH receptor stimulation (CJC-1295) and ghrelin receptor activation (Ipamorelin). Preclinical and in vitro studies suggest this combination may produce amplified, synergistic GH release—often 3–5 fold greater than either peptide alone—while maintaining pulsatile patterns and selectivity. Research models explore:

Mechanisms of GH axis regulation and hypothalamic-pituitary signaling
Potential influences on lean body mass, fat metabolism, insulin sensitivity, and energy expenditure
Recovery, tissue repair, muscle growth, and metabolic health in animal systems
Sleep quality, cognitive function, and anti-aging-related processes (via elevated GH/IGF-1 pathways)

The no-DAC form of CJC-1295 supports shorter, more natural GH pulses compared to DAC-extended versions, making the blend a model for studying physiological GH dynamics without prolonged elevation.

Potential Research Applications

In controlled laboratory settings, this blend is investigated for:

Growth hormone pulsatility and endocrine feedback loops
Metabolic regulation, body composition, and lipolysis models
Muscle regeneration, recovery from injury, and anabolic processes
Age-related decline in GH secretion and related physiological impacts
Synergistic secretagogue interactions and receptor cross-talk

Studies indicate good tolerability in models, with Ipamorelin’s selectivity potentially reducing off-target effects.

Important Notes

This blend remains unapproved for any human or clinical use. No therapeutic claims are implied, and development has not led to regulatory approval for medical applications. All products are sold strictly for research use only — not for diagnostic, therapeutic, or personal consumption. Researchers must use sterile techniques, proper reconstitution, and biosafety measures. Always verify purity and identity via independent lab analysis (COA) and follow institutional guidelines.